DB-1325 / DualityBio - LARVOL DELTA

DB-1325, a BCMA-targeting antibody-drug conjugate with a Duality Unique Payload, exhibits promising efficacy and safety in preclinical multiple myeloma treatment (AACR 2025) - "DB-1325 is a novel BCMA-targeting ADC comprised of belantamab and PDUP5, a Duality Unique Payload (DUP) inhibiting mRNA translation, conjugated through a cleavable linker. A proprietary inhibitor of mRNA translation PDUP5 was discovery through a campaign of medicinal chemical design and screening. DB-1325 is a novel and promising therapy for MM and currently in preclinical development as a first-in-class ADC with mRNA translation inhibitions as its major mode of action."

IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology